BCL2L1 and neoplasm: While encouraging anti-tumour activity in clinical trials has led to the approval of the Bcl-2 inhibitor, venetoclax, the therapeutic utility of dual Bcl-2/Bcl-xL inhibitors such as navitoclax has been limited by accompanying toxicities.